Work

A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer

Year: 2020

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2020.01.018

Authors: Karen A. Cadoo, Rachel N. Grisham, Roisin E. O'Cearbhaill, Nicole N. Boucicaut, Melissa Henson, Alexia Iasonos, Qin Zhou, Debra M. Sarasohn, Jacqueline Gallagher, Sara Kravetz, Dmitriy Zamarin, Vicky Makker, Paul J. Sabbatini, William P. Tew, Carol Aghajanian, Jason A. Konner

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W3000687425

FWCI: 0.16

Cites: 35

Cited by: 5

Related to: 10